MaxCyte MXCT Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$4.75M+53.7% | -$9.6M+9.4% | -$12.42M-7.4% | -$12.36M-31.8% | -$10.26M-7.7% | ||
| $1.05M-4.5% | $1.07M+1.4% | $1.07M+0.6% | $1.1M+1.8% | $1.1M-1.4% | ||
| $1.14M-62.5% | $706K-77.5% | $1.95M-42.0% | $3.51M-1.4% | $3.04M+0.8% | ||
| —— | $888.5K— | $888.5K— | $888.5K— | $888.5K— | ||
| —— | -$155K+61.2% | -$19K+81.2% | -$66K— | -$47K— | ||
| $743K-11.4% | -$4.8M— | $2.57M+12,348% | $238K+114% | $839K+145% | ||
| $380K+172% | —— | —— | -$223K+66.4% | -$531K-214% | ||
| -$3.64M+34.9% | -$383K+17.3% | —— | —— | -$5.59M-70.1% | ||
| $127K-50.0% | —— | —— | $886K+150% | $254K+870% | ||
| -$1K+75.0% | —— | -$21K+36.4% | -$22K-171% | -$4K0.0% | ||
| -$327K+75.3% | -$1.6M— | —— | -$1.51M-35.8% | -$1.33M-124% | ||
| $221K+22.1% | $215K+76.2% | $209K+74.2% | $197K+68.4% | $181K+56.0% | ||
| -$456K-64.0% | -$218K+23.5% | -$346K-65.6% | -$315K-181% | -$278K-170% | ||
| -$8.17M+43.3% | -$2.69M+65.6% | -$7.46M-69.8% | -$9.85M-104% | -$14.41M-36.4% | ||
| $72K-89.0% | $231K+57.1% | $300K-26.1% | $584K+98.6% | $653K-18.8% | ||
| —— | —— | —— | —— | $1.77M— | ||
| $25.12M-27.5% | $28.26M-13.1% | $34.51M-11.5% | $28.88M-7.8% | $34.65M-27.9% | ||
| $28M-39.9% | $38.16M+23.1% | $40M-7.0% | $31M-39.2% | $46.6M+35.3% | ||
| $150K— | —— | —— | —— | —— | ||
| $2.66M-72.1% | $9.68M— | $5.19M+43.9% | $1.54M-92.1% | $9.53M+166% | ||
| $5K-98.7% | $15K-93.1% | $14K-93.9% | $20K-95.5% | $383K-45.5% | ||
| $5K-98.7% | $105K-74.5% | $14K-93.9% | $154K-78.4% | $383K-45.5% | ||
| -$5.51M-22.4% | —— | -$2.25M-306% | -$8.16M— | -$4.5M+81.5% | ||
| $437K-50.6% | $427K-64.1% | $584K-57.9% | $751K-55.4% | $884K-55.4% | ||
| -$327K+75.3% | -$1.6M— | —— | -$1.51M-35.8% | -$1.33M-124% | ||
| -$456K-64.0% | -$218K+23.5% | -$346K-65.6% | -$315K-181% | -$278K-170% | ||
| -$69K-6.2% | $1.28M+346% | $29K-98.1% | -$708K-11.8% | -$65K+90.6% | ||
| $197K+203% | $151K-83.9% | $360K-48.4% | $100K— | $65K— | ||
| $14K— | $13K-53.6% | $15K+7.1% | —— | —— | ||
| $221K+22.1% | $215K+76.2% | $209K+74.2% | $197K+68.4% | $181K+56.0% | ||
| $150K— | —— | —— | —— | —— | ||
| $28M-39.9% | $38.16M+23.1% | $40M-7.0% | $31M-39.2% | $46.6M+35.3% | ||
| $24K— | $4K-93.5% | —— | —— | —— | ||
| -$456K-64.0% | -$218K+23.5% | -$346K-65.6% | -$315K-181% | -$278K-170% | ||
| —— | —— | —— | —— | $956K— | ||
| -$8.24M+45.3% | -$2.92M+63.4% | -$7.76M-61.7% | -$10.44M-104% | -$15.06M-32.5% | ||
| -$8.24M+45.3% | -$2.92M+63.4% | -$7.76M-61.7% | -$10.44M-104% | -$15.06M-32.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does MaxCyte generate?
- MaxCyte (MXCT) generated -$28.2M in operating cash flow over the trailing twelve months.
- What is MaxCyte's free cash flow?
- After $1.2M of capital expenditures, MaxCyte's free cash flow was -$29.4M over the trailing twelve months, up 10.9% year over year.
- Where does MaxCyte's cash flow data come from?
- Every line is extracted from MaxCyte's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
